SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.

N, Kreuzberger; C, Hirsch; KL, Chai; E, Tomlinson; Z, Khosravi; M, Popp; M, Neidhardt; V, Piechotta; S, Salomon; SJ, Valk; I, Monsef; C, Schmaderer; EM, Wood; C, So-Osman; DJ, Roberts; Z, McQuilten; LJ, Estcourt; N, Skoetz

doi:10.1002/14651858.cd013825.pub2

Public

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.

Shared by NobleBlocks on Sep 2, 2021 • 12:00 AM UTC

Authors:

Kreuzberger N

Hirsch C

Chai KL

Abstract

Background Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells of an infected host. They are being investigated as a potential therapy for coronavirus disease 2019 (COVID-19).Objectives To assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs for tre...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!